Kornimate/medical-research-clean huggingface dataset:
improving chronic nocturnal noninvasive ventilation: a multimodality approach

Conditions: Chronic Respiratory Failure; Non-invasive Ventilation

Summary: the aim of the data collection is to create an advanced reliable method to remotely monitor patient on chronic home non-invasive ventilation (niv), both regarding ventilatory efficacy and patient comfort, both in the hospital and at home by assessing gas exchange, lung mechanics and the interaction between the patient and the ventilator. for this purpose, we will set-up of databank of synchronously acquired datasets of already standard care monitored parameters during niv (transcutaneous monitoring of gas exchange; ventilator data including data on pva), and newly non-invasively acquired data on patient effort (emg, patient ratings) and lung (hyper)inflation (eit), during the set-up and follow-up of standard care chronic niv.

can be provided on request as the registry rules are no in dutch

Eligibility criteria:
inclusion criteria: * copd patients indicated for chronic home niv exclusion criteria: * not able to read the written information and/or sign the informed consent form * no possibility to perfrom measurements at home

Keywords: monitoring
comparison of btds (buprenorphine transdermal system) and placebo in osteoarthritic pain

Conditions: Pain; Osteoarthritis

Summary: the primary objective of this study is to evaluate the efficacy and safety of btds compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.

the primary objective of this study is to evaluate the efficacy and safety of buprenorphine transdermal system (btds) compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee who have a sub-optimal response to their non-opioid analgesic treatment and require opioid analgesics for pain control.

Eligibility criteria:
inclusion criteria: * males or females ages 40 years or older. * clinical diagnosis of osteoarthritis (oa) of the hip or knee. exclusion criteria: * subjects who have a current or past history of chronic disease(s), in addition to oa, requiring frequent analgesic therapy (e.g. headache, fibromyalgia, gout, rheumatoid arthritis, low back pain, and diabetic neuropathy).

Keywords: osteoarthritic pain
machine learning predict renal replacement therapy after cardiac surgery

Conditions: Machine Learning; Acute Kidney Injury; Renal Replacement Therapy; Prediction Models

Summary: cardiac surgery-associated acute kidney injury (csa-aki) is a major complication which may result in adverse impact on short- and long-term mortality. the researcher here developed several prediction models based on machine learning technique to allow early identification of patients who at the high risk of unfavorable kidney outcomes. the retrospective study comprised 2108 consecutive patients who underwent cardiac surgery from january 2017 to december 2020.


Eligibility criteria:
inclusion criteria: * age over 18 years who underwent cardiac surgery exclusion criteria: * data miss greater than 10%
price changes and hypothetical food purchases in adult grocery shoppers

Conditions: Effect of Taxes and Subsides on Food Purchases in Mothers

Summary: the goal of the proposed study is to apply experimental economics in an online grocery store shopping model to examine the effects of pricing on hypothetical food purchases

participants will be lean and overweight primary grocery shoppers aged 18 years and older. participants will be considered lean if their body mass index (bmi = kg/m2) is less than 29.9, overweight if their bmi is greater than or equal to 30.12 to meet eligibility for the study, participants must be the guardian of a child at least 2 years or older, do the primary grocery shopping for the family, they must also report being weekly household grocery shoppers, and purchase the majority of their household's groceries once a week.

Eligibility criteria:
inclusion criteria: 18 or older primary shopper in the household, at least one child over 2 years of age exclusion criteria: eating disorders, not liking study foods
regional differences in human immunodeficiency virus (hiv) testing

Conditions: HIV Seropositivity; CD4+ T Lymphocytopenia

Summary: this retrospective observational study aims at the examination of regional differences in the procedure of referral for serological hiv testing between eastern (new) and western (old) german federal states.

increasing incidence of hiv infections urges early recognition and timely introduction of therapy. regional differences in referral approach and patient behavior are presumably associated with considerable delays in infection recognition and therapy onset. comparison of records of new cases which were diagnosed in 2014 in several eastern federal states and a major western german city is expected to disclose whether the regionally preferred type of the primary care institution affects the time point of first diagnosis and the elapsed time since the emergence of the infection, as assessed by cluster of differentiation 4 positive (cd4+) lymphocyte counts and manifestation of clinical symptoms of immune deficiency.

Eligibility criteria:
inclusion criteria: * first-time hiv seropositivity exclusion criteria: * n/a
effects of a rehabilitation program on physical performance and disease self-management in rheumatoid arthritis.

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the effects of a group-based exercise and educational program for people with rheumatoid arthritis (ra) on physical performance and disease-self-management.

currently, the effectiveness of a program consisting of education to improve disease self-management combined with intensive exercises is not clear. in the present study the investigators developed a group-based program for people with ra consisting of physical exercise to increase physical performance (i.e. aerobic capacity and muscle strength) combined with an educational program to improve disease self-management (self-reported health status and self-efficacy). the investigators called it the 'fit program'. the aim of the present randomized controlled trial (rct) was to examine the effects of the fit program on aerobic capacity, muscle strength, self-reported health status and self-efficacy, in a population of people with ra. the investigators hypothesized that the fit-program would have beneficial effects on physical performance (ie. aerobic capacity and muscle strength) and disease self-management (i.e. perceived health status and self-efficacy components) compared to a waiting list control group (wlcgroup).

Eligibility criteria:
inclusion criteria: * medical diagnosis of ra according to the american college of rheumatology (acr) criteria * between 18 and 66 years of age exclusion criteria: * severe disease activity (disease activity score:das-28 \> 5.1) * cardiac or pulmonary diseases resulting in restrictions in their ability to follow a physical exercise program * a steinbrocker classification of functional capacity in ra ≥ 3 * no stable medication for the ra * intra-articular injections during the time of the study

Keywords: exercise education self-management rehabilitation
cosmetic effects of topical acetyl zingerone

Conditions: Wrinkle Appearance; Skin Pigment; Erythema; Side Effect; Microbiome; Lipidome

Summary: cosmeceuticals are an emerging market within dermatology and the growth of natural products and derivatives of natural products has accelerated in use within the field. here the investigators aimed to study the microbial and cosmetic effects of synoxyl az, the trade name for topical acetyl zingerone (az), a novel compound designed based on zingerone and curcumin.

cosmeceuticals are an emerging market within dermatology and the growth of natural products and derivatives of natural products has accelerated in use within the field. here the investigators aim to study synoxyl az, the trade name for topical acetyl zingerone (az), a novel compound designed based on zingerone and curcumin. both curcumin and zingerone are from the zingiberacea family of plants (also known as the ginger family). both have been widely studied and noted to have antibacterial effects and promote skin health effects. curcumin has been studied widely in recent years due to various microbial effects. az is a derivative that is similar to both zingerone and curcumin and has been noted to have many different activities including anti-inflammatory, antimicrobial, and antioxidant functions. however, there are no studies looking at how it modulates the skin cosmetically or the superficial microbiome. the aim of this study was to compare the cosmetic effects of az to a vehicle over an 8-week period.

Eligibility criteria:
inclusion criteria: * individuals aged 30-60 * healthy subjects exclusion criteria: * those that have had topical antibiotics within the past 4 weeks * those that have had oral antibiotics within past 4 weeks * those who have used systemic isotretinoin in the last 6 months * those with a known allergy to members of the ginger family * current smokers or 20 pack-year history of smoking or have smoked within the past 3 years * pregnant women * prisoners * those who have had any change to their hormonal birth control regimen in the last 4 weeks. * those with visible signs in the area of application of or on active treatment for cystic acne, eczema, seborrheic dermatitis, papulopustular rosacea at investigator discretion * those who have had a recent surgical or cosmetic procedure in the last 3 months that can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin injections, chemical peels, laser based therapies to the face, or face lift surgeries at investigator discretion

Keywords: ginger curcumin zingerone
comparison of acute effects of myofascial release and kinesio taping® in dysmenorrhea

Conditions: Kinesio Taping; Myofascial Release Technique; Pain; Primary Dysmenorrhea (PD)

Summary: dysmenorrhea is a physiological condition and one of the most common issues experienced during menstruation. this study aims to compare the acute effects of myofascial release technique (mrt) and kinesio taping® (kt) on pain severity, fatigue, and menstrual symptom severity in individuals with primary dysmenorrhea (pd).

a total of 45 individuals diagnosed with pd will be randomly assigned to one of three groups: mrt, kt, or control. pain severity and fatigue will be measured using the visual analog scale (vas), while menstrual symptom severity will be assessed with the menstrual symptom scale, both prior to and following the interventions. the mrt group will be received mrt for three consecutive days starting from the onset of menstruation, whereas the kt group will be applied kt application for a duration of 72 hours. the control group did not receive any form of intervention.

Eligibility criteria:
inclusion criteria: * daignosed with primary dysmenorrhea * regular menstruation in the past six months * experience menstrual pain ranging between 40-100 mm on the visual analog scale exclusion criteria: * diagnosis of secondary dysmenorrhea * a menstrual cycle length of less than 21 days or more than 35 days * a history of childbirth or pregnancy * use of pharmacological treatments for menstrual pain * a history of pelvic pathology or pelvic surgery * the presence of neurological or systemic diseases

Keywords: kinesio taping menstruation primary dysmenorrhea myofascial release technique physiotherapy
pediatric alliance for international neurogastrointestinal functional research

Conditions: Irritable Bowel Syndrome

Summary: to explore the predictive value of alarm signs ("red flags") for a diagnosis of functional gastrointestinal disorders (fgid) in children. to assess the natural history of pain predominant functional gastrointestinal disorders (fgid) in newly diagnosed pediatric patients. to document the benefit of various treatment regimens currently employed in managing fgid. to assess the short- and long-term impact of various fgid regimens. to allow physicians to gain a better understanding of the epidemiology of fgid. hypothesis: there are presenting symptoms or results from diagnostic tests that are more likely to associated with conditions different from fap or ibs. symptoms of children with fap/ibs change overtime regardless of the treatments used.


Eligibility criteria:
inclusion criteria: * males and females ages 4 through 16 years of age (up to the day of the 17th birthday) * presenting with chronic or intermittent abdominal pain of any severity lasting at least 2 months may participate in the registry. exclusion criteria: * subjects age 10 and above will be asked to complete the questionnaire themselves. those unable to complete the questionnaire (with only some help) should not be enrolled. * patients unable to participate in the program for at least 3 years should not be enrolled (i.e., anticipated move, etc.)
extended treatment with vancomycin for clostridium difficile colitis

Conditions: Clostridium Difficile Colitis

Summary: background: clostridium difficile-associated colitis is an infection of the large bowel, usually associated with previous use of antibiotics. the disease course may be complicated by fulminant disease requiring removal of the colon or by multiple recurrences requiring re-hospitalization. the incidence and severity of clostridium difficile infection is rising, and it poses an increasing burden on the health system. for example, in one of our previous studies we found that 804 in-patients and 568 out-patients had a positive test for clostridium difficile toxin at beaumont laboratories in 2003. the standard treatment is a 2 week course of vancomycin or metronidazole. the clinical response to metronidazole appears to be declining, and many practicing clinicians prefer vancomycin as a first-line treatment. the recurrence rate after the treatment is similar for vancomycin and metronidazole and is usually in the range of 15-25%, although recent reports noted a recurrence rate up to 50% during outbreaks with a virulent strain. recently, it has been suggested that a 2 week duration of treatment might not be adequate in clearing the infection. our hypothesis is that a prolongation of vancomycin treatment from 2 weeks to 4 weeks will lead to a decrease rate of recurrent clostridium difficile colitis.

methodology: patients with a first episode of clostridium difficile colitis will be offered a prolonged course of vancomycin. it will be disclosed that this is not the standard of care, but that a prolonged course might decrease the relapse rate. after the initial treatment with vancomycin 125 mg four times daily, the patients will be randomly assigned to receive either 2 weeks of vancomycin 125 mg four times daily or 2 weeks of placebo. the placebo solution will be prepared by our pharmacy to match the color and taste of the vancomycin solution. the initial 2 weeks of therapy for both groups will be dispensed at patients' pharmacy. patients will be called back at the end of 2 weeks and the blinded-phase drugs will be dispensed by our pharmacy staff. we will ask permission for a follow-up phone call at the end of treatment (1 month) and at a 3-month interval. the patients will be followed longitudinally for a 3-month period. at the end of the follow-up interval, a review of any new medical records of the patient will be made and the patient will be contacted by phone for further details.

Eligibility criteria:
inclusion criteria: * first episode of clostridium difficile colitis, defined by a positive toxin assay plus at least one of the following: diarrhea, toxic megacolon or leukocytosis. exclusion criteria: * previous diagnosis of clostridium difficile colitis * concomitant use of oral metronidazole, rifampin, rifaximin, nitazoxanide, sacharromyce boulardii or lactobacillus spp. * age less than 18 years-old * pregnancy.

Keywords: clostridium difficile colitis recurrence relapse vancomycin
feasibility of continuous noninvasive finger arterial blood pressure measurement for detection and staging of aortic stenosis

Conditions: Aortic Stenosis, Calcific

Summary: the primary purpose of this study is electronic data collection of arterial pressure waveform signals in patients with aortic stenosis. the collected digital pressure waveform data will be used to assess the feasibility of using the arterial pressure signal as a decision support tool for early detection of aortic stenosis conditions. furthermore we evaluate hemodynamic parameters before and after valve repair and its correlation with outcome.


Eligibility criteria:
inclusion criteria: * o patients with severe senile degenerative aortic valve stenosis * clinical team agrees on eligibility including assessment that tavr is appropriate for the subject * patients undergoing tavr via the femoral approach * patients who normally require a guiding catheter for central aortic pressure monitoring during the tavr procedure * patient must be 18 years old or older * patient, or legally authorized representative, has given consent to be in the study * patient height and weight are available prior to study * ability to perform a nexfin measurement at the left hand side. exclusion criteria: * o patients with contraindications for placement of aortic catheter * patients with mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation \>3+). * aortic valve is a congenital unicuspid or congenital bicuspid valve, or is noncalcified * patients being treated with an intra-aortic balloon pump * patients less than 40 kg in weight * female patients of childbearing potential with a known pregnancy * patient is currently participating in an investigational drug or another device study that clinically interferes with the study endpoints
viral infection and respiratory illness universal study[virus]: covid-19 registry

Conditions: Coronavirus

Summary: researchers are creating a real time covid-19 registry of current icu/hospital care patterns to allow evaluations of safety and observational effectiveness of covid-19 practices and to determine the variations in practice across hospitals.

investigators aim is to create a real time covid-19 registry of current icu/hospital care patterns to allow evaluations of safety and observational effectiveness of covid-19 practices and to determine the variations in practice across hospitals. such a set of standards would increase the quality of single and multi-center studies, national registries as well as aggregation syntheses such as meta-analyses. it will also be of utmost importance in tiring times of public health emergencies and will help understand practice variability and outcomes during covid-19 pandemic.

Eligibility criteria:
inclusion criteria: * covid-19 pcr positive (within 7 days) * covid-19 pcr pending * covid-19 high clinical suspicion exclusion criteria: * patient without prior research authorization (applicable to mayo clinic sites) * non covid-19 related admissions * repeated admission to icus/hospital

Keywords: covid19
effect of bacillus coagulans in adults with with functional constipation

Conditions: Constipation - Functional

Summary: the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of bacillus coagulans on various symptoms and fecal microbial diversity in adults with with functional constipation for 12 weeks.

a previous study has indicated that bacillus coagulans provided control of abdominal pain, less discomfort during defecation, and a more normalized defecation style, especially in adults with with functional constipation. therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of bacillus coagulans various symptoms and fecal microbial diversity in adults with with functional constipation for 8 weeks; the safety of the compound are also evaluated. the investigators examine constipation visual analogue scale, bristol stool form scale type 3 \& 4 ratio, visual analogue scale for irritable bowel syndrome (vas-ibs) questionnaire score, ibs-symptom severity scale, ibs quality-of-life questionnaire score, fecal microbial diversity at baseline, as well as after 8 weeks of intervention. eighty adults were administered either 400 mg of bacillus coagulans or a placebo each day for 8 weeks.

Eligibility criteria:
inclusion criteria: - function constipation by romes criteria iv exclusion criteria: * abnormal liver or renal function (more than twice the normal upper limit of the research institute) * uncontrolled diabetes mellitus (\>160 mg/dl of fasting blood sugar) * uncontrolled hypertension (\>160/100 mmhg) * uncontrolled thyroid diseases. * history of serious cerebro-cardiovascular diseases or cancer such as angina or myocardial infarction within 6 months * history of structural abnormalities of colon within 4 year * history of medication for probiotics and psychiatric diseases such as severe depression, schizophrenia, drug intoxication. * alcohol abuser * allergic reaction to this test food * those who participated in other drug clinical trials within 1 month from the screening date. * severe gastrointestinal symptoms such as heartburn and indigestion * those who are pregnant, lactating, or plan to become pregnant during the clinical trial * those who are judged to be unsuitable by the pi for other reasons
ivermectin vs combined hydroxychloroquine and antiretroviral drugs (art) among asymptomatic covid-19 infection

Conditions: Asymptomatic Infections; SARS-CoV2 Infection

Summary: this is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d\* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of sar-cov2 adult thai population. both study treatment regimens will have oral zinc sulfate combination treatment ( 200mg. twice daily). outcomes include safety and duration of detectable of sar-cov2 in nasopharyngeal/ throat (np) swab by polymerase chain reaction amplification (pcr) after treatment. 40-50 patients in each treatment arm is planned, with an interim analysis when approximately 50% of cases is enrolled.

* study procedure will be carried out after informed consent is obtained. * baseline physical exam and laboratory investigations will be performed. * eligible patients will be randomized to one of the two treatment arms. * symptoms and signs will be monitored daily. * np swab will be done at day5-7, and prior to discharge. * complete blood counts, blood chemistries, electrocardiography will be performed for adverse event monitoring within 5 days after end of study drugs' administration. * patients will be discharged at 2- 4 weeks after hospitalization, according to pcr results. * there will be 1-2 follow up visit at out patient clinic for np swab (patients with +ve last np swab before discharge), and blood tests. * additional 5-8 ml. of edta blood will be taken at baseline and weekly for antibody detection. * interim analysis of both safety and efficacy will be performed when approximately 50% of enrollment is achieved. * intention to treat analysis is planned at the completion of enrollment.

Eligibility criteria:
inclusion criteria: * sar-cov2 detected by pcr from np swab * asymptomatic or upper respiratory symptoms such as runny noses * no history of fever or oral temp \<37.8 degree celsius * informed consent obtained exclusion criteria: * fever or respiratory rate \>24/minute or oxygen saturation at room air\< 94% * any serious co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with hba1c \> 8%, chronic liver disease, lymphocyte count \<1,000cell/cu.mm. * history of ivermectin or any of the study drug allergy. * concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin * pregnant or lactating woman

Keywords: ivermectin hydroxychloroquine/darunavir/ritonavir sar-cov2 asymptomatic infection zinc sulfate